On October 24, 2022 Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, reported that Transcenta is invited to participate the 10th TEMTIA meeting in Paris, France, November 7 to 10 and present preclinical data of TST003, Transcenta’s first-in-class, high affinity humanized monoclonal antibody targeting Gremlin1 (Press release, Transcenta, OCT 24, 2022, View Source [SID1234622326]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the speech are as follows:
Topic：TST003, a first-in-class anti-Gremlin1 monoclonal antibody, blocks EMT and displays potent single agent anti-tumor activities in PDX models of multiple difficult-to-treat solid tumors
Date & Time: 9 November 2022, 3:30 pm-3:45 pm (Paris time)
Speaker: Dr. Xueming Qian, CEO, Transcenta
TEMTIA is an international meeting dedicated to the study of epithelial to mesenchymal transition (EMT). EMT process is triggered when epithelial cells loosen cohesiveness and adopt an individualized motile phenotype in link with the progressive loss of epithelial features. EMT was originally defined in the context of developmental stages and contributes to cancer progression and metastasis. EMT has shown to be an important mechanism for resistance to cancer therapies including checkpoint inhibitor immunotherapy.
About TST003
TST003 is a high affinity monoclonal antibody targeting Gremlin1, a member of TGFb superfamily. Gremlin1 protein is a highly conserved secreted protein and has shown to play important roles during development. Gremlin1 is highly upregulated in multiple solid tumors. Gremlin1 protein promotes epithelial mesenchymal transition. TST003 has shown promising single agent activities in patient-derived xenograft tumor models of multiple difficult-to-treat solid tumors resistant to checkpoint inhibitor including castration resistant prostate cancer and microsatellite stable colorectal cancer. TST003 also enhanced the anti-tumor activity of checkpoint inhibitor in syngeneic tumor model. TST003 has received FDA clearance for entering clinical testing in September, 2022.